The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Previously treated advanced unresectable/metastatic ESCC (progressed during/after 1L therapy) |
Tislelizumab |
Investigator-chosen therapy: paclitaxel, docetaxel, or irinotecan |
Primary Endpoints: OS (ITT Population) Key Secondary Endpoints: OS in patients with PD-L1 TAP ≥10%, ORR, PFS, DoR, HRQoL, safety |
